Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

  • In development
  • GID-TA11582
  • Expected publication date: TBC

Register as a stakeholder

20578-Pembrolizumab-for-Cutaneous-Squamous-Cell-Carcinoma-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)